Erratum: Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates (Proceedings of the National Academy of Sciences of the United States of America (2014) 111:11 (3955-3960) DOI:10.1073/pnas.1322937111);Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 11, 2014, Pages 3955-3960

  Dong, Yizhou ^a,b,c   Love, Kevin T ^a,c   Dorkin, J Robert ^a   Sirirungruang, Sasilada ^a   Zhang, Yunlong ^a   Chen, Delai ^a,c   Bogorad, Roman L ^a   Yin, Hao ^a   Chen, Yi ^a   Vegas, Arturo J ^a,c   Alabi, Christopher A ^a,b   Sahay, Gaurav ^a   Olejnik, Karsten T ^a   Wang, Weiheng ^a,c   Schroeder, Avi ^a,b   Lytton Jean, Abigail K R ^a   Siegwart, Daniel J ^a,b   Akinc, Akin ^d   Barnes, Carmen ^d   Barros, Scott A ^d   Carioto, Mary ^d   Fitzgerald, Kevin ^d   Hettinger, Julia ^d   Kumar, Varun ^d   Novobrantseva, Tatiana I ^d   Qin, June ^d   Querbes, William ^d   Koteliansky, Victor ^d   Langer, Robert ^a,b   Anderson, Daniel G ^a,b,c   more..

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d ALNYLAM PHARMACEUTICALS   (United States)

Author keywords

Lipopeptide nanomaterials; Liver genetic disorders; Tissue and cell specificity; Translational research

Indexed keywords

APOLIPOPROTEIN E; CKK E12; LIPOPEPTIDE; LIPOPEPTIDE NANOPARTICLE; NANOPARTICLE; PREALBUMIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL SPECIFICITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; ENDOTHELIUM CELL; GENE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER PARENCHYMA; MACACA FASCICULARIS; MOUSE; NONHUMAN; PRIMATE; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

LIPOPEPTIDE NANOMATERIALS; LIVER GENETIC DISORDERS; TISSUE AND CELL SPECIFICITY; TRANSLATIONAL RESEARCH;

ANIMALS; APOLIPOPROTEINS E; CRYOELECTRON MICROSCOPY; DRUG DELIVERY SYSTEMS; GENE SILENCING; HEPATOCYTES; LIPOPEPTIDES; MACACA FASCICULARIS; MICE; NANOPARTICLES; RATS; RNA, SMALL INTERFERING;

EID: 84896519424     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1404711111     Document Type: Erratum

References (33)

1. McClellan J, King MC (2010) Genetic heterogeneity in human disease. Cell 141(2): 210-217.
2. Krawczyk M, Müllenbach R, Weber SN, Zimmer V, Lammert F (2010) Genome-wide association studies and genetic risk assessment of liver diseases. Nat Rev Gastroenterol Hepatol 7(12):669-681.
3. Fire A, et al. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391(6669):806-811. (Pubitemid 28099681)
4. Davis ME (2009) The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: From concept to clinic. Mol Pharm 6(3):659-668.
5. Whitehead KA, Langer R, Anderson DG (2009) Knocking down barriers: Advances in siRNA delivery. Nat Rev Drug Discov 8(2):129-138.
6. Castanotto D, Rossi JJ (2009) The promises and pitfalls of RNA-interference-based therapeutics. Nature 457(7228):426-433.
7. Chen Y, Huang L (2008) Tumor-targeted delivery of siRNA by non-viral vector: Safe and effective cancer therapy. Expert Opin Drug Deliv 5(12):1301-1311.
8. Fenske DB, Cullis PR (2008) Liposomal nanomedicines. Expert Opin Drug Deliv 5(1): 25-44. (Pubitemid 351234108)
9. Rozema DB, et al. (2007) Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci USA 104(32):12982-12987. (Pubitemid 351737577)
10. Semple SC, et al. (2010) Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 28(2):172-176.
11. Woodrow KA, et al. (2009) Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater 8(6):526-533.
12. Akinc A, et al. (2008) A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 26(5):561-569. (Pubitemid 351668042)
13. Love KT, et al. (2010) Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA 107(5):1864-1869.
14. Yoo JW, Irvine DJ, Discher DE, Mitragotri S (2011) Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov 10(7):521-535.
15. Yang M, et al. (2011) Efficient cytosolic delivery of siRNA using HDL-mimicking nanoparticles. Small 7(5):568-573.
16. Marcovina SM, Morrisett JD (1995) Structure and metabolism of lipoprotein (a). Curr Opin Lipidol 6(3):136-145.
17. Mahley RW (1988) Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 240(4852):622-630.
18. Ng KK, Lovell JF, Zheng G (2011) Lipoprotein-inspired nanoparticles for cancer theranostics. Acc Chem Res 44(10):1105-1113.
19. Prata CA, et al. (2008) Lipophilic peptides for gene delivery. Bioconjug Chem 19(2):418-420. (Pubitemid 351294912)
20. Adami RC, et al. (2011) An amino acid-based amphoteric liposomal delivery system for systemic administration of siRNA. Mol Ther 19(6):1141-1151.
21. Margus H, Padari K, Pooga M (2012) Cell-penetrating peptides as versatile vehicles for oligonucleotide delivery. Mol Ther 20(3):525-533.
22. Futaki S, et al. (2001) Stearylated arginine-rich peptides: A new class of transfection systems. Bioconjug Chem 12(6):1005-1011. (Pubitemid 33136872)
23. McKenzie DL, Collard WT, Rice KG (1999) Comparative gene transfer efficiency of low molecular weight polylysine DNA-condensing peptides. J Pept Res 54(4):311-318. (Pubitemid 29459730)
24. Wadhwa MS, Collard WT, Adami RC,McKenzie DL, Rice KG (1997) Peptide-mediated gene delivery: Influence of peptide structure on gene expression. Bioconjug Chem 8(1):81-88. (Pubitemid 27064227)
25. Chen D, et al. (2012) Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation. J Am Chem Soc 134(16):6948-6951.
26. Abdel-Magid AF, Carson KG, Harris BD, Maryanoff CA, Shah RD (1996) Reductive amination of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive amination procedures (1). J Org Chem 61(11):3849-3862. (Pubitemid 126532674)
27. Bergeron RJ, Phanstiel OIV, Yao GW, Milstein S, Weimar WR (1994) Macromolecular self-assembly of diketopiperazine tetrapeptides. J Am Chem Soc 116(19):8479-8484. (Pubitemid 24315628)
28. Yin H, Cheng L, Langenbach R, Ju C (2007) Prostaglandin I(2) and E(2) mediate the protective effects of cyclooxygenase-2 in a mouse model of immune-mediated liver injury. Hepatology 45(1):159-169. (Pubitemid 46144375)
29. Novobrantseva TI, et al. (2012) Systemic RNAi-mediated gene silencing in nonhuman primate and rodent myeloid cells. Mol Ther Nucleic Acids 1:e4.
30. Akinc A, et al. (2010) Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 18(7):1357-1364.
31. Agnani G, et al. (1991) Interaction of LpB, LpB:E, LpB:C-III, and LpB:C-III:E lipoproteins with the low density lipoprotein receptor of HeLa cells. Arterioscler Thromb 11(4):1021-1029.
32. Gold S, Monaghan P, Mertens P, Jackson TA (2010) A clathrin independent macropinocytosis- like entry mechanism used by bluetongue virus-1 during infection of BHK cells. PLoS ONE 5(6):e11360.
33. Ito S, Maeda S (2009) Mouse models of transthyretin amyloidosis. Recent Advances in Transthyretin Evolution, Structure and Biological Functions, eds Richardson SJ, Cody V (Springer, Berlin), pp 261-280.